மருந்து தொழில் இல் இந்தியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருந்து தொழில் இல் இந்தியா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருந்து தொழில் இல் இந்தியா Today - Breaking & Trending Today

JB Chemicals: New launches, market share gains to drive growth

Exclusive content, features, opinions and comment - hand-picked by our editors, just for you.
Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
Track the industry of your choice with a daily newsletter specific to that
industry.
Stay on top of your investments. Track stock prices in your portfolio.
NOTE :
This product is a monthly auto renewal product.
Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
To cancel, communicate from your registered email id and send the mail with the request to assist@bsmail.in. Include your contact number for easy reference. Requests mailed to any other ID will not be acknowledged or actioned upon. ....

Visa Credit Card , Standard Digital , Business Standard , Seamless Sign Up , Business Standard Digital , Debit Cards , Net Banking , Payment Wallets , Jb Chemicals , Gastrointestinal And Dermatology Accounting , Pharmaceuticals Nec , Healthcare In India , Pharmaceutical Industry In India , Kohlberg Kravis Roberts , Pharmaceutical Industry , Sun Pharma , Health Sciences , விசா கடன் அட்டை , தரநிலை டிஜிட்டல் , வணிக தரநிலை , தடையற்ற அடையாளம் மேலே , வணிக தரநிலை டிஜிட்டல் , பற்று அட்டைகள் , நிகர வங்கி , கட்டணம் பணப்பைகள் , ஜ்ப் இரசாயனங்கள் ,

Union Cabinet Approves Production Linked Incentive Scheme For Pharmaceuticals

The Union Cabinet, chaired by the Prime Minister, Narendra Modi has approved Production Linked Incentive (PLI) Scheme for Pharmaceuticals over a period of Financial Year 2020-21 to 2028-29. The Scheme will benefit domestic manufacturers, help in creating employment and is expected to contribute to the availability of wider range of affordable medicines for consumers.
The scheme is expected to promote the production of high value products in the country and increase the value addition in exports. Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Powered by Capital Market - Live News ....

Narendra Modi , Union Cabinet , Scheme For Pharmaceuticals , Prime Minister , Production Linked Incentive , Financial Year , Capital Market , Healthcare In India , Pharmaceutical Industry In India , Value Products , நரேந்திர மோடி , தொழிற்சங்கம் மந்திரி சபை , திட்டம் க்கு மருந்துகள் , ப்ரைம் அமைச்சர் , ப்ரொடக்ஶந் இணைக்கப்பட்டுள்ளது ஊக்கத்தொகை , நிதி ஆண்டு , மூலதனம் சந்தை , சுகாதாரம் இல் இந்தியா , மருந்து தொழில் இல் இந்தியா , மதிப்பு ப்ராடக்ட்ஸ் ,

Deepak Nitrite Q3 PAT jumps 38% YoY to Rs 216 cr

Deepak Nitrite (DNL) reported 38.2% rise in consolidated net profit to Rs 216.56 crore on 10.3% rise in revenue from operations to Rs 1234.69 crore in Q3 FY21 over Q3 FY20.
Improvement in revenues was led by robust Y-o-Y improvement in the phenolics business aided by incremental contribution from Isopropyl Alcohol (IPA) products. Profit before tax grew by 37.7% to Rs 290.3 crore in Q3 FY21 over Q3 FY20. Current tax expense spiked 25.5% to Rs 63.64 crore in Q3 FY21 over Q3 FY20.
EBITDA stood at Rs 340 crore in Q3 FY21, up 25% over Q3 FY20. EBITDA margin grew by 330 basis points to 27.4% in Q3 FY21 over Q3 FY20. Margin accretion has been driven by the increased volumes and higher efficiency in plant operations of the phenolics business supported by better sourcing, logistics and marketing for the wider product basket including IPA, which commenced in Q1 of the current fiscal. ....

Deepak Mehta , Aatmanirbhar Bharat , Deepak Nitrite , Isopropyl Alcohol , Vaccine Diplomacy , Indian Government , Capital Market , Healthcare In India , Pharmaceutical Industry In India , Incentivise Manufacturing , Phenolics Plant , Downstream Products , Manufacturing Sector , தீபக் மேத்தா , தடுப்பூசி இராஜதந்திரம் , இந்தியன் அரசு , மூலதனம் சந்தை , சுகாதாரம் இல் இந்தியா , மருந்து தொழில் இல் இந்தியா , பினோலிக்ஸ் ஆலை , கீழ்நிலை ப்ராடக்ட்ஸ் , உற்பத்தி துறை ,

Aurobindo Pharma Q3 PAT spurts 318% to Rs 2,946 cr

The drug maker s consolidated net profit jumped 317.70% to Rs 2,946.32 crore on a 9.5% rise in net sales at Rs 6,353.13 crore in Q3 December 2020 over Q3 December 2019.
Consolidated profit before tax (PBT) soared 326.90% to Rs 4,005.40 crore in Q3 December 2020 as against Rs 938.17 crore in Q3 December 2019. Current tax expense for the quarter surged 397.80% to Rs 1,083.15 crore as against Rs 217.17 crore in Q3 December 2019. The Q3 result was declared after trading hours yesterday, 10 February 2021.
EBITDA grew 13.3% to Rs 1368.60 crore in Q3 FY21 over Rs 1208 crore in Q3 FY20. EBITDA margin stood at 21.5% in Q3 December 2020 as against 20.5% in Q3 December 2019.
Formulation revenue for the quarter recorded a growth of 11.3% Y-o-Y to Rs 5,682.40 crore and accounted for 89.3% of total revenues. ....

Aurobindo Pharma , Research Development , Capital Market , Pharmaceutical Industry In India , Economy Of India , Health Care , Active Pharmaceutical Ingredients , Managing Director , N Govindarajan , Generic Pharmaceuticals , அரவிந்தோ பார்மா , ஆராய்ச்சி வளர்ச்சி , மூலதனம் சந்தை , மருந்து தொழில் இல் இந்தியா , பொருளாதாரம் ஆஃப் இந்தியா , ஆரோக்கியம் பராமரிப்பு , செயலில் மருந்து பொருட்கள் , நிர்வகித்தல் இயக்குனர் , ச்சனியான கோவிந்தராஜன் , ஜெநெரிக் மருந்துகள் ,

J B Chemicals soars after Q3 PAT zooms 132% YoY to Rs 154 cr

J B Chemicals & Pharmaceuticals jumped 8.68% to Rs 1172 after the company s consolidated net profit zoomed 132.2% to Rs 154.28 crore on a 27.9% rise in net sales to Rs 548.22 crore in Q3 FY21 over Q3 FY20.Consolidated profit before tax (PBT) surged 136% to Rs 208.46 crore in Q3 FY21 over Q3 FY20. J.B Chemicals said PBT for Q3 FY21 includes non-recurring income of Rs 34 crore related to sale of product registration, marketing authorization along with trademark. Current tax expense was sharply higher at Rs 49.68 crore in Q3 FY21 as compared to Rs 20.11 crore in Q3 FY20.
The company said operational and revenue momentum continued with strong contributions from Domestic formulations and International business. Domestic formulations maintained secular outperformance compared to IPM growth rates, driven by strength in chronic segments and expanding prescriber coverage. ....

Nikhil Chopra , Jb Chemicals Pharmaceuticals , Capital Market , Healthcare In India , Pharmaceutical Industry In India , Consolidated Ebitda , Jb Chemicals , Jb Chemicals Amp Pharmaceuticals , Pharmaceutical Dosage Forms , நிகில் சோப்ரா , ஜ்ப் இரசாயனங்கள் மருந்துகள் , மூலதனம் சந்தை , சுகாதாரம் இல் இந்தியா , மருந்து தொழில் இல் இந்தியா , ஜ்ப் இரசாயனங்கள் , ஜ்ப் இரசாயனங்கள் ஆம்ப் மருந்துகள் , மருந்து அளவு வடிவங்கள் ,